Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL899438 | 0.84 | MEN1 (0.59) | MEN1KMT2AMAPK1ALDH1A1NPSR1 | |
| SCHEMBL12310937 | 0.83 | CYP2C9 (0.49) | MEN1KMT2AMAPK1ALDH1A1NPSR1 | |
| SCHEMBL6705858 | 0.82 | KMT2A (0.49) | MEN1KMT2AMAPK1NPSR1CYP2C9 | |
| SCHEMBL12263825 | 0.82 | KMT2A (0.62) | MEN1KMT2AMAPK1POLBTDP1 | |
| SCHEMBL7763901 | 0.82 | KMT2A (0.51) | MEN1KMT2AMAPK1ALDH1A1POLB | |
| SCHEMBL6705840 | 0.81 | POLB (0.51) | MEN1KMT2AMAPK1ALDH1A1NPSR1 | |
| SCHEMBL12691912 | 0.78 | MEN1 (0.48) | MEN1KMT2AMAPK1ALDH1A1NPSR1 | |
| SCHEMBL12263823 | 0.78 | ATM (0.45) | MEN1KMT2AMAPK1ALDH1A1NPSR1 | |
| SCHEMBL12899997 | 0.76 | CYP2C9 (0.46) | MEN1KMT2AMAPK1ALDH1A1NPSR1 | |
| SCHEMBL6708232 | 0.74 | ATM (0.57) | MAPK1ALDH1A1CYP2C9CYP2C19POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212177-B2 | Antiviral compounds and methods of making and using thereof | VERSITECH LIMITED (HK) | 2015-12-15 | — | — | US | disclosed |
| US-9212177-B2 | Antiviral compounds and methods of making and using thereof | VERSITECH LIMITED (HK) | 2015-12-15 | — | — | US | disclosed |
| EP-2462138-B1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING | VERSITECH LTD (CN) | 2014-09-24 | — | — | EP | disclosed |
| US-20110212975-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | THE UNIVERSITY OF HONG KONG | 2011-09-01 | — | — | US | disclosed |
| US-20110212975-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | THE UNIVERSITY OF HONG KONG | 2011-09-01 | — | — | US | disclosed |
| WO-2011015037-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THERE OF CROSS REFERENCE TO RELATED APPLICATIONS | THE UNIVERSITY OF HONGKONG (CN) | 2011-02-10 | — | — | WO | disclosed |
| US-20040157262-A1 | Conjugates of haptens to beta-lactam derivatives and their use for detecting and/or quantifying haptens in solution and device for implementation thereof | KOHL MICHEL (BE) | 2004-08-12 | — | — | US | disclosed |
| US-20030235877-A1 | Conjugates of haptens to beta-lactam derivatives and their use for detecting and/or quantifying haptens in solution and device for implementation thereof | LA REGION WALLONE (BE) | 2003-12-25 | — | — | US | disclosed |
| US-6436649-B1 | COMPETITIVE BINDING WITH ANTI-HAPTEN ANTIBODY IN SOLUTION CONTAINING REPORTER MOLECULE SUBSTRATE; ADDING B-LACTAMASE QUANTITATIVE ANALYSIS USING VISIBLE OR ULTRAVIOLET RADIATION | LE REGION WALLONE (BE) | 2002-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212975-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | VIP, H1-3, MAVS | MEN1 2290/4885KMT2A 1268/4885MAPK1 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.